Health care giant Johnson & Johnson on Friday announced a sweeping voluntary agreement with the Trump Administration, aiming to significantly lower out-of-pocket medication costs for millions of Americans while securing a strategic exemption from U.S. tariffs on its pharmaceutical products.
The deal centers on a partnership with TrumpRx.gov, a new direct-to-patient platform. Through this portal, American patients will be able to purchase J&J medicines at “significantly discounted rates,” effectively bringing U.S. drug prices in line with those found in other developed nations.
The agreement addresses long-standing concerns regarding the cost of prescription drugs in the United States. Key pillars of the deal include:
-
Direct-to-Consumer Savings: Integration with TrumpRx.gov to provide immediate discounts to patients.
-
Global Price Parity: A commitment to ensure American patients and the Medicaid program pay prices comparable to those in other developed markets.
-
Tariff Exemptions: In exchange for these price concessions, J&J’s pharmaceutical products will be exempt from U.S. tariffs, a move intended to stabilize the supply chain.
“Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” Joaquin Duato, chairman and CEO of Johnson & Johnson said.
Alongside the pricing agreement, J&J is accelerating its $55 billion U.S. investment plan, which aims to domesticate the manufacturing of the “vast majority” of its advanced medicines by 2029.
The company unveiled plans for two new major facilities:
-
Pennsylvania: A next-generation cell therapy manufacturing site.
-
North Carolina: A state-of-the-art drug product manufacturing facility.
These projects build on existing momentum in North Carolina, where J&J is already constructing a $2 billion biologics facility in Wilson—expected to create 5,000 jobs—and a recently secured biopharmaceutical site in Holly Springs.
The move signals a shift in how major pharmaceutical companies navigate trade and healthcare policy. By aligning with the administration’s “America First” manufacturing goals and drug-pricing transparency, J&J is positioning itself as a domestic leader in the “innovation powerhouse” sector.
The company expects to announce further U.S.-based investments later this year.
